Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

EMPEROR-Reduced Label Analysis

Here is a brief preview of this blast: Last week, FDA approved Jardiance for the treatment of HFrEF (view updated Jardiance label here; previous FENIX insight). The approval was based on results from the EMPEROR-Reduced CVOT which was first presented at ESC 2020; previous FENIX insight). As a reminder, BI/Lilly will be presenting full results from EMPEROR-Preserved as a Hot Line session at ESC 2021 on August 27 at 11:25AM ET (view ESC session). Recall, in July 2021, BI/Lilly announced positive topline results from the Ph3 EMPEROR-Preserved trial, but it did not provide any information on the magnitude of effect (previous FENIX insight). Below, FENIX provides thoughts on the new Jardiance HFrEF indication, including a favors/disfavors analysis for the HF market.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.